Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by equities researchers at Stifel Nicolaus from ...
Barclays lowered the firm’s price target on 10x Genomics (TXG) to $15 from $18 and keeps an Overweight rating on the shares.Maximize Your ...
Despite a challenging macro environment, 10x Genomics Inc (TXG) focuses on product innovation and biopharma expansion to ...
National Bank Financial boosted their FY2025 earnings per share (EPS) estimates for Torex Gold Resources in a report released ...
StockStory.org on MSN2d
10x Genomics (NASDAQ:TXG) Exceeds Q4 Expectations But Full-Year Sales Guidance Misses ExpectationsBiotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results , but sales fell by 10.3% year on year to $165 million.
Check the time stamp on this data. Updated AI-Generated Signals for 10x Genomics Inc. (TXG) available here: TXG. Type a few symbols and Take a Trial. The signals for these will appear immediately on ...
Genomics company 10x and Harvard University have agreed to resolve a patent lawsuit against 10x's rival Vizgen four days into ...
PLEASANTON, Calif. (AP) — PLEASANTON, Calif. (AP) — 10x Genomics Inc. (TXG) on Wednesday reported a loss of $49 million in its fourth quarter. The Pleasanton, California-based company said it had a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback